This publication describes the recent trends of drug overdose deaths in the United States (U.S.) and the benefits of adopting harm reduction approaches.
Resources and Tools
In Los Angeles, New York, Houston, Philadelphia, and Washington, D.C., a National Institutes of Health funded clinical trial, known as INTEGRA, is evaluating the efficacy of delivering integrated HIV and substance use disorder care via mobile clinics.
A recent study published in Drug and Alcohol Dependence found evidence for racial/ethnic disparities in buprenorphine distribution across the United States.
This document provides a quick overview of the federal discretionary funding programs that support essential aspects of the nation’s HIV response.
Achieving the goals of the Ending the HIV Epidemic (EHE) Initiative depends on doing more to strengthen communities, reduce the harm associated with drug use, and prevent disease transmission.
This policy brief identified states potentially at risk for an HIV or HCV outbreak and used data from multiple sources to examine rural-urban differences in 1) state-level infectious disease surveillance, prevention activities, and collaboration with stakeholders; 2) local health department-level
Because of naloxone’s ability to reverse opioid overdose and its ease of use, by July 15, 2017, all 50 states and the District of Columbia had passed legislation to improve naloxone access, as one strategy to reduce opioid overdose morbidity and mortality.